COCP News and Press, Cocrystal Pharma Inc. From 05/10/19

                                                              – Company is well positioned to achieve multiple corporate, clini...

Cocrystal Pharma (NASDAQ: COCP ): FY GAAP EPS of -$1.75. More news on: Cocrystal Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement of important new treatments for influenza – –  Clinic...

I have been studying what effect uplisting has on the stock price of individual stocks. My first article concluded that a profit exceeding 25% was available in 65% of stocks that had uplisted during 2015 but that profit evaporated within the first year after uplisting. Only 10% of these same...

BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today ...

Gainers:  Boxlight Corporation (NASDAQ: BOXL ) +47% . Microbot Medical (NASDAQ: MBOT ) +33% . Regional Health Properties (NYSEMKT: RHE ) +33% . Blink Charging (NASDAQ: BLNK ) +27% . iFresh (NASDAQ: IFMK ) +18% . Planet Green Holdings (NYSEMKT: PLAG ) +15% . Daxor Corporation (NY...

- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination therapy to include approved HCV DAAs (direct antiviral agents) - Company rep...